Pfizer

News
CHMP turns down Neuraxpharm, Apellis drugs

CHMP turns down Neuraxpharm, Apellis drugs

The EMA’s human medicines committee refused marketing approvals for two drugs from Neuraxpharm and Apellis at its January meeting, but both companies have said they will a

Market Access
M&A

A year of major M&A ahead?

The previous few years have seen a slowdown in M&A across the industry, as companies take a cautious approach to expansion.